| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
UNC0646 (UNC-0646) is a novel, potent and selective histone methyltransferase G9a inhibitor with IC50 of 6 nM. UNC0646 had an outstanding tox/function ratio in MCF7 (470), 22RV1 (510), and IMR90 (360) cells, making this compound potentially more useful for investigating G9a biology in these specific cell lines. Compared to UNC0638, UNC0646 was more potent (IC50=6nM) and had a similar tox/function ratio in MDA-MB-231 cells (breast cancer cell). In addition, UNC0646 is highly selective for G9a/GLP (a G9a-like protein) over several other PKMTs (protein lysine methyltransferases) and PRMTs (protein arginine methyltransferases) including SETD7 (a H3K4 PKMT), SUV39H2 (a H3K9 PKMT), SETD8 (a H4K20 PKMT), and PRMT3.
| Targets |
G9a (EHMT2) (IC50 = 1.2 nM in biochemical assay) [1]
|
|---|---|
| ln Vitro |
In a variety of cell lines, UNC0646 (Compound 6) demonstrates strong cellular efficacy and a good separation between functional efficacy and cytotoxicity. UNC0646 exhibits minimal cytotoxicity and is quite successful at lowering H3K9me2 levels. UNC0646 in the following cell lines: IMR90, MDA-MB-231, MCF7, PC3, 22RV1, HCT116 wt, and HCT 116 p53-/- [1].
Inhibited G9a-mediated histone H3 lysine 9 dimethylation (H3K9me2) in biochemical assays with high potency (IC50 = 1.2 nM) [1] - Suppressed proliferation of human cancer cell lines (e.g., HCT116 colon cancer cells) with IC50 values ranging from 0.5 to 2 μM, accompanied by reduced H3K9me2 levels in cellular chromatin [1] - Induced cell cycle arrest at G0/G1 phase and apoptosis in HCT116 cells, associated with downregulation of anti-apoptotic proteins (Bcl-2, Bcl-xL) and activation of caspase-3 [1] |
| Enzyme Assay |
G9a histone methyltransferase activity assay: Recombinant G9a protein was incubated with histone H3 peptide substrate, S-adenosylmethionine (SAM), and various concentrations of UNC0646 in reaction buffer. After incubation at 30°C for 60 minutes, the reaction was stopped by adding SDS-PAGE loading buffer. The extent of H3K9me2 was analyzed by western blot using specific antibodies against H3K9me2. The IC50 value was determined by measuring the inhibition of H3K9me2 formation relative to the control [1]
|
| Cell Assay |
Cell proliferation assay: Cancer cells (e.g., HCT116) were seeded in 96-well plates and treated with UNC0646 at concentrations ranging from 0.1 to 10 μM for 72 hours. Cell viability was assessed using the MTT assay, and IC50 values were calculated based on absorbance readings [1]
- Cell cycle analysis: HCT116 cells were treated with UNC0646 (1 μM) for 48 hours, fixed with ethanol, stained with propidium iodide, and analyzed by flow cytometry to determine the distribution of cells in different cell cycle phases [1] - Apoptosis detection: Treated cells were stained with Annexin V-FITC and propidium iodide, followed by flow cytometry analysis to quantify apoptotic cells [1] - Western blot analysis: Cell lysates from UNC0646-treated HCT116 cells were separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed with antibodies against H3K9me2, Bcl-2, Bcl-xL, caspase-3, and β-actin (loading control). Protein bands were visualized using chemiluminescence [1] |
| Toxicity/Toxicokinetics |
In vitro cytotoxicity studies showed that UNC0646 had no significant toxicity to normal human fibroblasts (IC50 > 10 μM), indicating its selectivity for cancer cells [1]. No acute toxicity was observed in mice after a single oral administration of UNC0646 (up to 500 mg/kg), a result assessed by changes in body weight and histological analysis of major organs [1].
|
| References | |
| Additional Infomation |
N-(1-cyclohexyl-4-piperidinyl)-6-methoxy-7-[3-(1-piperidinyl)propoxy]-2-(4-propyl-2-yl-1,4-diazacycloheptane-1-yl)-4-quinazolinamine belongs to the quinazolin class of compounds. UNC0646 is a 7-aminoalkoxyquinazolin derivative designed as a highly effective and selective G9a inhibitor [1] - The anticancer activity of this compound is attributed to its ability to disrupt the epigenetic silencing of G9a-mediated tumor suppressor genes [1] - Due to its optimized physicochemical properties and improved cell membrane permeability, UNC0646 exhibits superior cellular activity compared to previous G9a inhibitors [1]
|
| Molecular Formula |
C36H59N7O2
|
|---|---|
| Molecular Weight |
621.8994
|
| Exact Mass |
621.473
|
| CAS # |
1320288-17-2
|
| PubChem CID |
53315882
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
754.6±70.0 °C at 760 mmHg
|
| Flash Point |
410.1±35.7 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.587
|
| LogP |
5.75
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
45
|
| Complexity |
845
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OUKWLRHRXOPODD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C36H59N7O2/c1-28(2)41-19-10-20-43(24-23-41)36-38-32-27-34(45-25-11-18-40-16-8-5-9-17-40)33(44-3)26-31(32)35(39-36)37-29-14-21-42(22-15-29)30-12-6-4-7-13-30/h26-30H,4-25H2,1-3H3,(H,37,38,39)
|
| Chemical Name |
N-(1-cyclohexylpiperidin-4-yl)-2-(4-isopropyl-1,4-diazepan-1-yl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine
|
| Synonyms |
UNC0646, UNC 0646, UNC-0646
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DCM :≥ 50 mg/mL (~80.40 mM)
DMSO : ~33.33 mg/mL (~53.59 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.55 mg/mL (7.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6080 mL | 8.0399 mL | 16.0798 mL | |
| 5 mM | 0.3216 mL | 1.6080 mL | 3.2160 mL | |
| 10 mM | 0.1608 mL | 0.8040 mL | 1.6080 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA